KR20180034589A - 면역 반응을 유도하기 위한 신규한 방법 - Google Patents

면역 반응을 유도하기 위한 신규한 방법 Download PDF

Info

Publication number
KR20180034589A
KR20180034589A KR1020187005661A KR20187005661A KR20180034589A KR 20180034589 A KR20180034589 A KR 20180034589A KR 1020187005661 A KR1020187005661 A KR 1020187005661A KR 20187005661 A KR20187005661 A KR 20187005661A KR 20180034589 A KR20180034589 A KR 20180034589A
Authority
KR
South Korea
Prior art keywords
polypeptide
adenovirus
antigen
related antigen
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187005661A
Other languages
English (en)
Korean (ko)
Inventor
마리에-앙쥬 데모이티에
마리에-노일레 도너
나디아 오크드
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20180034589A publication Critical patent/KR20180034589A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/761Adenovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/235Adenoviridae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187005661A 2015-07-27 2016-07-25 면역 반응을 유도하기 위한 신규한 방법 Withdrawn KR20180034589A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1513176.6 2015-07-27
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response
PCT/EP2016/067622 WO2017017050A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
KR20180034589A true KR20180034589A (ko) 2018-04-04

Family

ID=54106649

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187005661A Withdrawn KR20180034589A (ko) 2015-07-27 2016-07-25 면역 반응을 유도하기 위한 신규한 방법

Country Status (15)

Country Link
US (4) US20180216081A1 (https=)
EP (2) EP3328420A1 (https=)
JP (2) JP2018524393A (https=)
KR (1) KR20180034589A (https=)
CN (2) CN108367061A (https=)
AR (1) AR105470A1 (https=)
AU (1) AU2016301029B2 (https=)
BE (2) BE1023915B1 (https=)
BR (2) BR112018001683A2 (https=)
CA (2) CA2993277A1 (https=)
EA (1) EA201890355A1 (https=)
GB (1) GB201513176D0 (https=)
IL (1) IL257071A (https=)
MX (2) MX2018001213A (https=)
WO (2) WO2017017050A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3436591B1 (en) * 2016-03-31 2023-01-04 The European Molecular Biology Laboratory Adenoviral coat protein derived delivery vehicles
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN111527213A (zh) 2017-10-16 2020-08-11 葛兰素史密丝克莱恩生物有限公司 具有两个编码rsv抗原蛋白或片段的表达盒的腺病毒载体
CA3084358A1 (en) * 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Enhanced promoter
US20200299651A1 (en) * 2017-10-16 2020-09-24 Glaxosmithkline Biologicals Sa Simian adenoviral vectors with two expression cassettes
AU2018351308B2 (en) * 2017-10-16 2021-12-02 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
GB201721069D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.
JP2021526831A (ja) * 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
WO2020033876A1 (en) * 2018-08-10 2020-02-13 Nantbio, Inc. Cellular adjuvants for viral infection
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗
CA3153133A1 (en) * 2019-09-30 2021-04-08 Chris Bartolome Adeno-associated virus (aav) systems for treatment of genetic hearing loss
CN113088538A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
US20240033334A1 (en) * 2020-12-04 2024-02-01 Gritstone Bio, Inc. Compositions and methods of use thereof
WO2023034783A1 (en) * 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Tuberculosis vaccines
CN118662620A (zh) * 2023-03-15 2024-09-20 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200901109T1 (tr) 1995-09-01 2012-02-21 Corixa Corporation Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US9592284B2 (en) 2004-04-28 2017-03-14 The Trustees Of The University Of Pennsylvania Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost
EP2426141B1 (en) * 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
WO2006133911A2 (en) * 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
EP2463362B1 (en) * 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2391638B1 (en) * 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
SI2528621T1 (sl) * 2010-01-27 2017-01-31 Glaxosmithkline Biologicals S.A., Modificirani tuberkolozni antigeni
EP2560680B1 (en) * 2010-04-16 2018-11-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Chimpanzee adenoviral vector-based filovirus vaccines
PL2651436T3 (pl) * 2010-12-14 2016-10-31 Kompozycja antygenów mykobakteryjnych
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
CN107921118B (zh) 2015-06-12 2022-11-08 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽

Also Published As

Publication number Publication date
EA201890355A1 (ru) 2018-08-31
JP2018521666A (ja) 2018-08-09
BE1023915A1 (fr) 2017-09-12
BE1023915B1 (fr) 2018-01-31
AU2016301029A1 (en) 2018-02-01
JP2018524393A (ja) 2018-08-30
WO2017017049A1 (en) 2017-02-02
BE1023916B1 (fr) 2018-01-22
EP3328420A1 (en) 2018-06-06
EP3328421A1 (en) 2018-06-06
WO2017017050A1 (en) 2017-02-02
AR105470A1 (es) 2017-10-04
CN108135991A (zh) 2018-06-08
US20210060150A1 (en) 2021-03-04
US20180250375A1 (en) 2018-09-06
US20180216081A1 (en) 2018-08-02
CA2993371A1 (en) 2017-02-02
IL257071A (en) 2018-03-29
CN108367061A (zh) 2018-08-03
BE1023916A9 (fr) 2018-02-12
MX2018001215A (es) 2018-04-13
BE1023915A9 (fr) 2018-01-24
US20210386846A1 (en) 2021-12-16
US11110159B2 (en) 2021-09-07
GB201513176D0 (en) 2015-09-09
BR112018001572A2 (pt) 2018-11-06
BR112018001683A2 (pt) 2018-09-18
MX2018001213A (es) 2018-04-13
AU2016301029B2 (en) 2019-08-22
CA2993277A1 (en) 2017-02-02
BE1023916A1 (fr) 2017-09-12

Similar Documents

Publication Publication Date Title
KR20180034589A (ko) 면역 반응을 유도하기 위한 신규한 방법
AU2019271972B2 (en) Adenovirus polynucleotides and polypeptides
AU2022203504B2 (en) Oncolytic tumor viruses and methods of use
AU2019204982B2 (en) Recombinant HCMV and RhCMV Vectors and Uses Thereof
JP2024073576A (ja) 改変アデノウイルス
AU2017305176B2 (en) Compositions and methods of replication deficient adenoviral vectors for vaccine applications
KR101763093B1 (ko) 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
KR101668163B1 (ko) Cmv용 백신으로서의 조건부 복제 시토메갈로바이러스
AU2018295421B2 (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR20230046313A (ko) 다중에피토프 백신 카세트
JP7698678B2 (ja) エプスタインバールウイルス抗原構築物
KR20210013589A (ko) 면역 체크포인트 억제제 공동-발현 벡터
KR20210090650A (ko) 알파바이러스 신생항원 벡터 및 인터페론 억제제
AU2017258857A1 (en) Subfamily E simian adenovirus A1309, A1321, A1325, A1295 and A1322 and uses thereof
KR20220041844A (ko) Hiv 항원 및 mhc 복합체
KR20230006825A (ko) 전염성 질병 항원 및 백신
KR20230014694A (ko) 항원-코딩 카세트
CN116940589A (zh) 重组sars-cov-2疫苗
TWI918097B (zh) 經修飾之腺病毒
DK2391638T3 (en) Abeadenovirus nucleic acid and amino acid sequences, vectors containing them, and uses thereof.
RU2800361C2 (ru) Стабильные составы цитомегаловируса
KR20230117163A (ko) 상동 아데노바이러스 백신접종

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination